Akamai And Delve Dig Into Online Video, Cardiorobotics Snags $11.6M for Snake-Like Surgery Robot, Longworth Collects $122M, & More Boston-Area Deals News
New England tech and life sciences firms forged several interesting new partnerships this week.
—Apperian, a Boston-based startup developing enterprise-oriented iPhone applications, raised $1 million in a Series A venture round led by CommonAngels of Lexington, MA.
—Cambridge, MA-based Akamai (NASDAQ: AKAM) teamed with Seattle’s Delve Networks to provide a new online platform for publishing videos and distributing them to any digital media player. The new service will compete against that offered by Cambridge-based Brightcove.
—Cardiorobotics of Newport, RI, and Pittsburgh, PA, raised $11.6 million in a Series A round from Eagle Ventures, the Slater Technology Fund, the Pittsburgh Life Sciences Greenhouse, and others. Eric wrote a nice profile of the startup’s efforts to develop a “snake robot” that would make heart surgeries less invasive.
—Advanced Electron Beams of Worcester, MA, closed a Series C round of financing worth $14.2 million. Flagship Ventures led the deal, which was joined by return investors Agman Partners, Atlas Venture, GE, General Catalyst Partners, and RockPort Capital Partners.
—Cancer drug developer Ariad Pharmaceuticals (NASDAQ: ARIA) of Cambridge netted $30.9 million in an offering of 19 million new shares of stock-–$3 million worth of which were purchased by CEO Harvey Berger.
—Boston-based data-storage firm Iron Mountain (NYSE:IRM) announced a planned notes offering worth $450 million.
—IT-focused venture firm Longworth Venture Partners of Waltham, MA, reportedly raised $122 million of a targeted $180 million for its third fund.
—Cambridge-based drug developer Alnylam Pharmaceuticals (NASDAQ:ALNY) inked a deal with Vancouver-based Tekmira Pharmaceuticals (TSX:TKM) to develop new particles to deliver RNA-interference drugs. Financial terms of the agreement were not disclosed.
—Idenix Pharmaceuticals (NASDAQ:IDIX), also of Cambridge, priced a secondary public offering of 7.25 million shares at $3.14 each. Idenix develops treatments for Hepatitis C.